Avalo Therapeutics, Inc. (AVTX) Tops Q3 EPS by 99c

Avalo Therapeutics, Inc. (NASDAQ: AVTX) reported Q3 EPS of ($0.11), $0.99 better than the analyst estimate of ($1.10). Revenue for the quarter came in at $240 thousand versus the consensus estimate of $1 million.

For earnings history and earnings-related data on Avalo Therapeutics, Inc. (AVTX) click here.

You May Also Be Interested In

• Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
• Jefferies sees range-bound India markets amid macro headwinds
• Adobe Systems (ADBE) Tops Q3 EPS by 6c, Offers Guidance